Nektar’s Phase II alopecia extension reveals late responders to IL-2 therapy

In a week with few movers on clinical data, the biggest was Nektar’s 18% gain following a Phase IIb readout from its IL-1 modulator in alopecia areata.

Nektar Therapeutics (NASDAQ:NKTR) rose 18% Monday, bringing its market cap above $2 billion, after the company said rezpegaldesleukin (rezpeg) drove additional hair regrowth in patients with severe alopecia areata during a 16-week extension of the Phase II REZOLVE-AA study. The company proposed a $250 million follow-on offering after market close...